RTP Mobile Logo
Select Publications

Brice P et al. Classical Hodgkin lymphoma. Lancet 2021;398(10310):1518-27. Abstract

Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract

Craddock C and Friedberg JW. Immunotherapy for hematologic malignancies. J Clin Oncol

2021;39(5):343-5. Abstract

Friedberg JW. An oncology Renaissance. J Clin Oncol 2021;39(25):2737-8. Abstract

Herrera AF et al. SWOG S1826: A phase III, randomized study of nivolumab plus AVD orbrentuximab vedotin plus AVD in patients with newly diagnosed advanced stage classicalHodgkin lymphoma. ASH 2020;Abstract 2969.

Hutchings M et al. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine inpatients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematol Oncol 2021;39(2):185-95. Abstract

Kalakonda N et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7(7):e511-22. Abstract

Kumar A et al. Brentuximab vedotin combined with chemotherapy in patients with newlydiagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol 2021; 39(20):2257-65. Abstract

Matasar MJ et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):678-89. Abstract

Munshi PN et al. American Society of Transplantation and Cellular Therapy, Center ofInternational Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma. Transplant Cell Ther 2021;27(9):720-8. Abstract

Nowakowski GS et al. Addition of lenalidomide to R-CHOP improves outcomes in newlydiagnosed diffuse large B-cell lymphoma in a randomized phase II US Intergroup StudyECOG-ACRIN E1412. J Clin Oncol 2021;39(12):1329-38. Abstract

Reagan PM and Friedberg JW. Axicabtagene ciloleucel and brexucabtagene autoleucel inrelapsed and refractory diffuse large B-cell and mantle cell lymphomas. Future Oncol 2021;17(11):1269-83. Abstract

Salles G et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21(&):978-88. Abstract

Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract

Smith MR et al. ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab(BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS. ASCO 2021;Abstract 7503.

Straus DJ et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8(6):e410-21. Abstract

Yasenchak CA et al. Frontline brentuximab vedotin as monotherapy or in combination forolder Hodgkin lymphoma patients. ASCO 2020;Abstract 8032.